Anna Ivanova, a legal counsel at BRACE Law Firm, published a legal commentary in the Pharmaceutical Vestnik journal regarding the proper legal structuring of sponsorship advertising for pharmaceutical companies.

As Ivanova noted, current legislation does not provide a statutory definition of a sponsorship agreement (“SA”), nor does it establish an exhaustive list of sponsored events. However, a systemic interpretation defines an SA as a contract between a sponsor and a sponsored party under which the sponsor provides financial or other material support to execute events in exchange for the mandatory dissemination of advertising concerning a specific person.

Can parties characterize sponsorship as a charitable activity? No, because charity constitutes a voluntary, gratuitous transfer of property, including funds, or the uncompensated performance of work and provision of services. In contrast, sponsors typically provide financial assistance in exchange for the placement of promotional information. Consequently, courts qualify a sponsorship agreement as a contract for consideration (an onerous transaction).

If a pharmaceutical company provides sponsorship support to the organizer of a medical or pharmaceutical event gratuitously and without specifying a particular purpose, courts may reclassify the contract as a deed of gift pursuant to Paragraph 1 of Article 572 of the Civil Code of the Russian Federation. If the sponsorship contribution is gratuitous but designated for specific purposes, courts may qualify it as a donation agreement. In a notable judicial precedent, the Arbitrazh Court of the City of Saint Petersburg and the Leningrad Region rejected arguments attempting to reclassify sponsorship agreements as deeds of gift, citing the presence of reciprocal consideration in the form of sponsor advertising (Decision dated August 7, 2020, in Case No. A56-63066/2019). The court concluded that a sponsorship agreement can only be reclassified as a deed of gift if the contract lacks a specified sponsorship purpose and contains no provisions for consideration.

Therefore, when drafting a sponsorship agreement, legal counsels must pay close attention to clauses governing consideration and the targeted allocation of sponsorship funds.

Most frequently, life sciences companies sponsor scientific medical and pharmaceutical events, such as conferences, webinars, and symposia. The mandatory identification of a specific entity as the sponsor serves as the core criterion distinguishing sponsorship advertising from standard promotional materials and donations. Furthermore, the dissemination of sponsorship advertising by pharmaceutical companies remains subject to specialized constraints, as their operations are heavily regulated not only by advertising laws but also by healthcare and pharmaceutical regulations.

Compliance officers must rigorously ensure that agreements do not violate the statutory restrictions imposed on pharmaceutical organizations interacting with healthcare professionals (“HCPs”). Specifically, Article 74 of Federal Law No. 323-FZ dated November 21, 2011, “On the Basics of Health Protection of Citizens in the Russian Federation,” strictly prohibits HCPs from accepting gifts, monetary funds, entertainment, recreation, or travel expenses from pharmaceutical companies and their representatives. Exceptions apply to compensation under clinical trial agreements for medicines and medical devices, as well as remuneration for pedagogical or scientific activities. When structuring a sponsorship agreement, BRACE recommends incorporating a specific compliance clause stipulating that the event organizer bears full liability for performing the contract in strict accordance with healthcare and pharmaceutical laws.

If a sponsorship agreement includes provisions to advertise the pharmaceutical company's specific products, that portion of the contract technically falls outside the scope of a pure sponsorship agreement. The law envisions only a single form of reciprocal consideration—the mention of the specific entity as a sponsor—although it does not explicitly prohibit adding product information alongside sponsor details.

Certain judicial bodies classify sponsorship agreements as contracts for the provision of services for consideration, based on the reciprocal services rendered to the sponsor (Resolution of the Ninth Arbitrazh Appellate Court No. 09AP-50398/2019 dated February 4, 2020, in Case No. A40-75828/2019).

Conversely, if a contract solely specifies the terms for placing promotional materials for a pharmaceutical organization's products, courts will treat it as a standard advertising services agreement.

The complete article and legal commentary are available on the publication's official website: https://pharmvestnik.ru/articles/Kak-pravilno-oformit-sponsorskuu-reklamu-farmacevticheskih-kompanii-Ne-korysti-radi.html, as well as here.

 PDF Version